Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Glecirasib |
Synonyms | |
Therapy Description |
Glecirasib (JAB-21822) is an inhibitor of KRAS G12C, with potential antitumor activity (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3089-3089). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Glecirasib | JAB21822|JAB 21822|JAB-21822 | KRAS G12C inhibitor 34 | Glecirasib (JAB-21822) is an inhibitor of KRAS G12C, with potential antitumor activity (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3089-3089). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05002270 | Phase Ib/II | Cetuximab + Glecirasib Glecirasib | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | Recruiting | USA | 0 |